

Media release

Straumann AGM: shareholders approve all proposals of the Board of Directors

- *Dividend of CHF 3.75 per share approved*
- *Entire Board of Directors reelected; CEO Gilbert Achermann elected as a new member of the Board*
- *Amendments to articles of association approved*
- *Annual report and new compensation report approved*

Basel, 20 March 2009: At their Annual General Meeting (AGM) today in Basel, the shareholders of Straumann AG approved all the proposals put forward by the Board of Directors. 652 shareholders attended the meeting and a total of 10 230 033 voting shares were represented, corresponding to 65% of the overall share capital.

The meeting approved the appropriation of the available earnings, which totaled CHF 593.4 million. CHF 58.4 million thereof were allocated to the 2008 dividend, corresponding to a payout ratio of 33% of net profit. Despite the weak economy, Straumann is maintaining the same level of dividend payout as in the previous year. The dividend of CHF 3.75 per share will be paid as of 25 March 2009.

The shareholders approved a number of changes in the articles of association including a reduction in the term of office of the Directors from three years to one. As a result, the entire Board was reelected. Straumann's CEO Gilbert Achermann was newly elected to the Board, which now comprises seven members.

The shareholders also approved the 2008 Annual Report, including the compensation report, the 2008 Financial Statements, in addition to the discharge of the Board of Directors for their activities in 2008. PricewaterhouseCoopers of Basel was reappointed as Statutory Auditors and Group Auditors for a further term of one year.

The AGM also approved several changes to the articles of association, which predominantly concern adaptations to best practices and to changes in the Swiss Code of Obligations.

Dental medicine not immune to difficult economic situation in 2008

Dr. h.c. Rudolf Maag, Chairman of the Board, explained that dentistry had not been immune to the difficult economic situation in 2008. Nevertheless, Straumann achieved net revenue growth of 15% in local currencies and gained market share.

He also noted that implant dentistry has scarcely penetrated the tooth replacement market in most countries. Furthermore, there is huge potential for example in Russia, India and China, where implantology has yet to become established. Low penetration rates also characterize the CAD/CAM-based dental prosthetics segment, where only a small proportion of dental laboratories have invested in this technology, which may

determine the future of dentistry. Regenerative solutions are also only just beginning to establish themselves in a number of countries.

There is therefore no reason to suggest that key markets will not expand in the mid to long term and Straumann continues to work on the assumption that its most important market, implant dentistry, is capable of achieving growth rates of 15% again. Furthermore, the company also firmly believes that it can exceed the growth rates of the markets where it operates, thanks to its broad access to customers, its superior technology platform, its innovation power and its highly qualified staff. The company aims to achieve this and, at the same time, to ensure a sustainable increase in profitability.

2010 AGM

In 2010, the ordinary general meeting of the shareholders will be convened on 26 March at the same location (Basel Trade-Fair Congress Center).

Concerning forward looking statements

This release contains certain “forward-looking statements”, which can be identified by the use of terminology such as “for a further term”, “expected”, “future”, “will”, “assumption”, “is capable”, “can exceed”, “mid and long term”, “objective” and “sustainable”, or similar wording. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group’s products, the potential for the Group’s products to become obsolete, the Group’s ability to defend its intellectual property, the Group’s ability to develop and commercialize new products in a timely manner, the dynamic and competitive environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group’s ability to generate revenues and profitability, and the Group’s ability to realize its expansion projects in a timely manner. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.

About Straumann

Headquartered in Basel, Switzerland, the Straumann Group (SIX: STMN) is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2200 people worldwide and its products and services are available in more than 60 countries through its broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.
Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01
E-mail: investor.relations@straumann.com or corporate.communication@straumann.com
Homepage: www.straumann.com

Contact:

Mark Hill, Corporate Communication
+41 (0)61 965 13 21

Fabian Hildbrand, Investor Relations
+41 (0)61 965 13 27

Key reporting dates in 2009

28 April	Q1 sales
11 August	Q2 sales and H1 results
29 October	Q3 and 9M sales

Details and further information are available on www.straumann.com.